Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00469209 · BASELINE

Baseline characteristics

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients · Source last updated 2020-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      20
    2. group Id
      BG001
      value
      20
    3. group Id
      BG002
      value
      20
    4. group Id
      BG003
      value
      60
    units
    Participants
groups
  1. description
    Melphalan 100 mg/m\^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
    id
    BG000
    title
    No Bortezomib
  2. description
    Bortezomib (Level 1) 1.0 mg/m\^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m\^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
    id
    BG001
    title
    Bortezomib 1.0 mg/m^2
  3. description
    Bortezomib (Level 2) 1.5 mg/m\^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
    id
    BG002
    title
    Bortezomib 1.5 mg/m^2
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          47
          upper Limit
          70
          value
          61
        2. group Id
          BG001
          lower Limit
          45
          upper Limit
          67
          value
          59
        3. group Id
          BG002
          lower Limit
          49
          upper Limit
          75
          value
          64
        4. group Id
          BG003
          lower Limit
          45
          upper Limit
          75
          value
          60
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          12
        2. group Id
          BG001
          value
          9
        3. group Id
          BG002
          value
          6
        4. group Id
          BG003
          value
          27
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          8
        2. group Id
          BG001
          value
          11
        3. group Id
          BG002
          value
          14
        4. group Id
          BG003
          value
          33
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          20
        2. group Id
          BG001
          value
          20
        3. group Id
          BG002
          value
          20
        4. group Id
          BG003
          value
          60
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      20
    2. group Id
      BG001
      value
      20
    3. group Id
      BG002
      value
      20
    4. group Id
      BG003
      value
      60
    units
    Participants
groups
  1. description
    Melphalan 100 mg/m\^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
    id
    BG000
    title
    No Bortezomib
  2. description
    Bortezomib (Level 1) 1.0 mg/m\^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m\^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
    id
    BG001
    title
    Bortezomib 1.0 mg/m^2
  3. description
    Bortezomib (Level 2) 1.5 mg/m\^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
    id
    BG002
    title
    Bortezomib 1.5 mg/m^2
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          47
          upper Limit
          70
          value
          61
        2. group Id
          BG001
          lower Limit
          45
          upper Limit
          67
          value
          59
        3. group Id
          BG002
          lower Limit
          49
          upper Limit
          75
          value
          64
        4. group Id
          BG003
          lower Limit
          45
          upper Limit
          75
          value
          60
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          12
        2. group Id
          BG001
          value
          9
        3. group Id
          BG002
          value
          6
        4. group Id
          BG003
          value
          27
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          8
        2. group Id
          BG001
          value
          11
        3. group Id
          BG002
          value
          14
        4. group Id
          BG003
          value
          33
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          20
        2. group Id
          BG001
          value
          20
        3. group Id
          BG002
          value
          20
        4. group Id
          BG003
          value
          60
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice